ATE446090T1 - Thiadiazolidinone als gsk3-inhibitoren - Google Patents

Thiadiazolidinone als gsk3-inhibitoren

Info

Publication number: ATE446090T1
Authority: AT; Austria
Prior art keywords: thiadiazolidinones; gsk3 inhibitors; gsk3; inhibitors
Prior art date: 2004-04-05

Application number

AT05075779T

Other languages

English (en)

Inventor

Gil Martinez

Diaz Isabel Dorronsoro

Cascon Mercedes Alonso

Pliego Gema Panizodel

Huerta Ana Fuertes

Puerto Maria Jose Perez

Padilla Miguel Medina

Original Assignee

Noscira Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-05

Filing date

2005-04-04

Publication date

2009-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE446090(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-04 Application filed by Noscira Sa filed Critical Noscira Sa

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE446090T1 publication Critical patent/ATE446090T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Psychiatry (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)

AT05075779T 2004-04-05 2005-04-04 Thiadiazolidinone als gsk3-inhibitoren ATE446090T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04075997A EP1586318A1 (de)	2004-04-05	2004-04-05	Thiadiazolidinone als GSK3-Inhibitoren

Publications (1)

Publication Number	Publication Date
ATE446090T1 true ATE446090T1 (de)	2009-11-15

Family

ID=34928129

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05075779T ATE446090T1 (de)	2004-04-05	2005-04-04	Thiadiazolidinone als gsk3-inhibitoren

Country Status (30)

Country	Link
US (2)	US7531561B2 (de)
EP (2)	EP1586318A1 (de)
JP (1)	JP4995076B2 (de)
KR (1)	KR101151647B1 (de)
CN (1)	CN1946398B (de)
AR (2)	AR048820A1 (de)
AT (1)	ATE446090T1 (de)
AU (1)	AU2005230392B2 (de)
BR (1)	BRPI0508788A (de)
CA (1)	CA2559740C (de)
CY (1)	CY1109724T1 (de)
DE (1)	DE602005017215D1 (de)
DK (1)	DK1586319T3 (de)
EC (1)	ECSP066858A (de)
ES (1)	ES2335505T3 (de)
HK (1)	HK1100426A1 (de)
HR (1)	HRP20100032T1 (de)
IL (1)	IL178125A (de)
MA (1)	MA28515B1 (de)
MX (1)	MXPA06011194A (de)
NO (1)	NO332751B1 (de)
NZ (1)	NZ549904A (de)
PL (1)	PL1586319T3 (de)
PT (1)	PT1586319E (de)
RS (1)	RS51340B (de)
RU (1)	RU2379300C2 (de)
SI (1)	SI1586319T1 (de)
TW (1)	TWI352084B (de)
WO (1)	WO2005097117A1 (de)
ZA (1)	ZA200608221B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ296087B6 (cs)	2000-05-11	2006-01-11	Consejo Superior Investigaciones Cientificas	Farmaceutický prostredek pro lécbu nemoci, na nízse podílí heterocyklické inhibitory glykogensyntázakinázy GSK-3
EP1586318A1 (de) *	2004-04-05	2005-10-19	Neuropharma S.A.U.	Thiadiazolidinone als GSK3-Inhibitoren
WO2006045581A1 (en) *	2004-10-21	2006-05-04	Neuropharma, S.A.	The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
ES2258406B1 (es) *	2005-02-10	2007-12-01	Neuropharma, S.A.	Uso de compuestos heterociclicos como agentes neurogenicos.
EP1749523A1 (de) *	2005-07-29	2007-02-07	Neuropharma, S.A.	GSK-3 Inhibitoren
EP2043633B1 (de) *	2006-07-18	2016-07-06	University of Rochester	Thiadiazolidinonderivate zur behandlung von krebs
WO2008012031A2 (en) *	2006-07-25	2008-01-31	Universität Bern	Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
ES2445791T3 (es)	2006-10-21	2014-03-05	Abbvie Deutschland Gmbh & Co Kg	Compuestos hetererocíclicos y su uso como inhibidores de la glucógeno sintasa cinasa 3
KR100829468B1 (ko) *	2007-01-17	2008-05-16	한국화학연구원	신규한 1,2,4-티아다이아졸리딘-3,5-다이온 화합물 및 이의제조방법
KR100837785B1 (ko) *	2007-01-17	2008-06-13	한국화학연구원	1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009097995A1 (de) *	2008-02-07	2009-08-13	Sanofi-Aventis	Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2310372B1 (de)	2008-07-09	2012-05-23	Sanofi	Heterocyclische Verbindungen, Verfahren zu ihrer Herstellung, Arzneimitteln mit diesen Verbindungen und ihre Verwendung
EP2177510A1 (de)	2008-10-17	2010-04-21	Universität des Saarlandes	Allosterische Proteinkinasemodulatoren
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en)	2009-08-26	2012-04-27	Sanofi Sa	Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011151359A1 (en) *	2010-06-02	2011-12-08	Noscira, S.A.	Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2621914B1 (de)	2010-09-27	2016-12-28	Abbott GmbH & Co. KG	Heterocyclische verbindungen und ihre verwendung als glycogensynthasekinase-3-inhibitoren
WO2012065065A1 (en) *	2010-11-12	2012-05-18	Follica, Inc.	Methods and compositions for modulating hair growth, wound healing and scar revision
WO2012078649A1 (en)	2010-12-06	2012-06-14	Follica, Inc.	Methods for treating baldness and promoting hair growth
US9090592B2 (en)	2010-12-30	2015-07-28	AbbVie Deutschland GmbH & Co. KG	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de)	2011-03-08	2015-02-18	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8865750B2 (en)	2011-04-28	2014-10-21	The Regents Of The University Of Michigan	Small molecule inhibitors of RGS proteins
EP2527323A1 (de)	2011-05-24	2012-11-28	Noscira, S.A.	Harnstoffcarbonyldisulfidderivate und deren therapeutische Verwendungen
WO2012170657A1 (en) *	2011-06-07	2012-12-13	Georgetown University	Targeting gsk-3beta for the treatment of parkinson's disease
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (de)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT2838888T (pt)	2012-02-24	2017-07-18	Asd Therapeutics Partners Llc	Tiadiazolidinedionas como inibidores da gsk-3
RU2509155C1 (ru) *	2012-10-25	2014-03-10	Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук	Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
CN103992312A (zh) *	2013-02-18	2014-08-20	江苏欧威医药有限公司	1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
CN103992313A (zh) *	2013-02-18	2014-08-20	江苏欧威医药有限公司	1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途
WO2015075051A1 (en)	2013-11-19	2015-05-28	Universitaet Des Saarlandes	Allosteric inhibitors of atypical protein kinases c
WO2015155738A2 (en)	2014-04-09	2015-10-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
ES2960601T3 (es)	2014-06-12	2024-03-05	Cedars Sinai Medical Center	Composiciones y métodos para el tratamiento del cáncer
CN107151235B (zh) *	2016-03-04	2019-12-13	上海市计划生育科学研究所	噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
CA3017341A1 (en) *	2016-03-10	2017-09-14	Alma Mater Studiorum - Universita Di Bologna	Treatment of cdkl5 disorders with gsk3.beta. inhibitor tideglusib
GB201617820D0 (en) *	2016-10-21	2016-12-07	King S College London	Dental treatment
WO2018226721A1 (en) *	2017-06-06	2018-12-13	The J. David Gladstone Institutes	Compositions and methods for reactivating latent immunodeficiency virus using a gsk-3 inhibitor
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN113827592B (zh) *	2020-06-24	2024-06-18	中国科学院上海药物研究所	一种噻二唑烷二酮基化合物在治疗致病性感染中的应用
WO2022182699A1 (en)	2021-02-24	2022-09-01	Teva Pharmaceuticals International Gmbh	Solid state forms of tideglusib and process for preparation thereof
CA3219537A1 (en)	2021-05-21	2022-11-24	Michael Snape	Method of treating rna repeat mediated diseases with rna repeat binding compound
EP4094760A1 (de)	2021-05-24	2022-11-30	Consejo Superior De Investigaciones Científicas	Thiadiazolidinone zur verwendung in der behandlung von gliedergürtel-muskeldystrophie
CN115197167B (zh) *	2022-07-22	2023-07-28	中国药科大学	1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
CN117986202B (zh) *	2024-04-03	2024-06-14	中国药科大学	具有ptpn2抑制活性的1，2，4-噻二唑烷-3，5-二酮化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ296087B6 (cs) *	2000-05-11	2006-01-11	Consejo Superior Investigaciones Cientificas	Farmaceutický prostredek pro lécbu nemoci, na nízse podílí heterocyklické inhibitory glykogensyntázakinázy GSK-3
ES2166328B1 (es) *	2000-05-11	2003-09-16	Consejo Superior Investigacion	Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
EP1586318A1 (de) *	2004-04-05	2005-10-19	Neuropharma S.A.U.	Thiadiazolidinone als GSK3-Inhibitoren

2004
- 2004-04-05 EP EP04075997A patent/EP1586318A1/de not_active Withdrawn
2005
- 2005-04-01 AR ARP050101293A patent/AR048820A1/es not_active Application Discontinuation
- 2005-04-04 AU AU2005230392A patent/AU2005230392B2/en active Active
- 2005-04-04 EP EP05075779A patent/EP1586319B1/de active Active
- 2005-04-04 TW TW094110769A patent/TWI352084B/zh active
- 2005-04-04 RS RSP-2010/0017A patent/RS51340B/en unknown
- 2005-04-04 PL PL05075779T patent/PL1586319T3/pl unknown
- 2005-04-04 AT AT05075779T patent/ATE446090T1/de active
- 2005-04-04 ES ES05075779T patent/ES2335505T3/es active Active
- 2005-04-04 ZA ZA200608221A patent/ZA200608221B/xx unknown
- 2005-04-04 BR BRPI0508788-0A patent/BRPI0508788A/pt not_active IP Right Cessation
- 2005-04-04 MX MXPA06011194A patent/MXPA06011194A/es active IP Right Grant
- 2005-04-04 JP JP2007506716A patent/JP4995076B2/ja active Active
- 2005-04-04 PT PT05075779T patent/PT1586319E/pt unknown
- 2005-04-04 WO PCT/EP2005/003613 patent/WO2005097117A1/en active Application Filing
- 2005-04-04 DE DE602005017215T patent/DE602005017215D1/de active Active
- 2005-04-04 CA CA2559740A patent/CA2559740C/en active Active
- 2005-04-04 RU RU2006139030/04A patent/RU2379300C2/ru active
- 2005-04-04 SI SI200530879T patent/SI1586319T1/sl unknown
- 2005-04-04 DK DK05075779.8T patent/DK1586319T3/da active
- 2005-04-04 NZ NZ549904A patent/NZ549904A/en active IP Right Revival
- 2005-04-04 CN CN2005800121414A patent/CN1946398B/zh active Active
- 2005-04-05 US US11/098,610 patent/US7531561B2/en active Active
2006
- 2006-09-14 IL IL178125A patent/IL178125A/en active IP Right Grant
- 2006-09-18 EC EC2006006858A patent/ECSP066858A/es unknown
- 2006-10-02 MA MA29364A patent/MA28515B1/fr unknown
- 2006-10-02 NO NO20064456A patent/NO332751B1/no unknown
- 2006-10-11 KR KR1020067021121A patent/KR101151647B1/ko active IP Right Grant
2007
- 2007-07-31 HK HK07108359.1A patent/HK1100426A1/xx unknown
2009
- 2009-04-22 US US12/428,442 patent/US8158661B2/en active Active
2010
- 2010-01-13 CY CY20101100036T patent/CY1109724T1/el unknown
- 2010-01-18 HR HR20100032T patent/HRP20100032T1/hr unknown
2016
- 2016-04-27 AR ARP160101182A patent/AR104417A2/es unknown

Also Published As

Publication number	Publication date
KR101151647B1 (ko)	2012-06-08
MXPA06011194A (es)	2007-03-21
AU2005230392B2 (en)	2011-03-24
PT1586319E (pt)	2010-01-21
BRPI0508788A (pt)	2007-09-04
US20090233971A1 (en)	2009-09-17
AR104417A2 (es)	2017-07-19
NO332751B1 (no)	2013-01-07
EP1586318A1 (de)	2005-10-19
MA28515B1 (fr)	2007-04-03
CA2559740A1 (en)	2005-10-20
NO20064456L (no)	2006-10-02
ZA200608221B (en)	2008-08-27
DK1586319T3 (da)	2010-02-08
PL1586319T3 (pl)	2010-06-30
US20050222220A1 (en)	2005-10-06
JP2007531782A (ja)	2007-11-08
CY1109724T1 (el)	2014-08-13
ECSP066858A (es)	2007-01-26
TWI352084B (en)	2011-11-11
RU2006139030A (ru)	2008-05-20
DE602005017215D1 (de)	2009-12-03
AU2005230392A1 (en)	2005-10-20
IL178125A (en)	2012-01-31
AR048820A1 (es)	2006-05-31
TW200538119A (en)	2005-12-01
US8158661B2 (en)	2012-04-17
US7531561B2 (en)	2009-05-12
WO2005097117A1 (en)	2005-10-20
SI1586319T1 (sl)	2010-02-26
EP1586319B1 (de)	2009-10-21
HRP20100032T1 (hr)	2010-03-31
CN1946398B (zh)	2011-03-30
KR20060131976A (ko)	2006-12-20
HK1100426A1 (en)	2007-09-21
IL178125A0 (en)	2006-12-31
CA2559740C (en)	2014-06-10
CN1946398A (zh)	2007-04-11
RS51340B (en)	2011-02-28
NZ549904A (en)	2010-08-27
ES2335505T3 (es)	2010-03-29
JP4995076B2 (ja)	2012-08-08
EP1586319A1 (de)	2005-10-19
RU2379300C2 (ru)	2010-01-20

Publication	Publication Date	Title
ATE446090T1 (de)	2009-11-15	Thiadiazolidinone als gsk3-inhibitoren
ATE423121T1 (de)	2009-03-15	Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
ATE400271T1 (de)	2008-07-15	Aryl-pyridinderivate als 11-beta-hsd1-hemmer
DE602005002517D1 (de)	2007-10-31	Drehtisch
ATE420076T1 (de)	2009-01-15	Indozolonderivate als 11b-hsd1-inhibitoren
ATE478868T1 (de)	2010-09-15	Pyrrolodihydroisochinoline als pde10- inhibitoren
DE602004004628D1 (de)	2007-03-22	Schlauchendsprühgerät
DK1799690T3 (da)	2008-06-30	Thiazolyl-dihydro-indazoler
ATE462692T1 (de)	2010-04-15	3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer
DE602005012725D1 (de)	2009-03-26	Htvermögens
FI20045304A (fi)	2004-08-24	Repijämurskain
DE502005004695D1 (de)	2008-08-28	Sicherheitsfangseil
DE602005000169D1 (de)	2006-11-23	Nahtprüfvorrichtung
ATE454934T1 (de)	2010-01-15	Drehteller
AT500198B8 (de)	2007-02-15	Ladewagen
DE602005010518D1 (de)	2008-12-04	Reifenvulkanisierblase
FI20050681A0 (fi)	2005-06-22	Paikoitusmenetelmä
DE502005003159D1 (de)	2008-04-24	Kettenstichnähvorrichtung
AT500249A3 (de)	2006-03-15	Scheibenegge
DE502005007349D1 (de)	2009-07-09	Lagerbox
FI20045462A (fi)	2006-05-30	Embossauselin
SE0403198D0 (sv)	2004-12-30	Analyzer
ATA482004A (de)	2005-07-15	Tuba-dämpfer
DE602005017159D1 (de)	2009-11-26	Oxysteroid-dehydrogenase-inhibitoren
ES1059458Y (es)	2005-08-01	Marcapaginas ex libris

Legal Events

Date	Code	Title	Description
2010-07-15	UEP	Publication of translation of european patent specification	Ref document number: 1586319 Country of ref document: EP

Date

Code

Title

Description

2010-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1586319

Country of ref document: EP